NCT01614691View on ClinicalTrials.gov

Safety and Efficacy of SPARC1203 in Allergic Rhinitis

PHASE2CompletedINTERVENTIONAL
Enrollment

159

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

November 30, 2012

Study Completion Date

March 31, 2013

Conditions
Allergic Rhinitis
Interventions
DRUG

SPARC1203

Active

DRUG

Placebo

Placebo

Trial Locations (1)

Unknown

SPARC Site 1, Hanover

All Listed Sponsors
lead

Sun Pharma Advanced Research Company Limited

INDUSTRY

NCT01614691 - Safety and Efficacy of SPARC1203 in Allergic Rhinitis | Biotech Hunter | Biotech Hunter